CAG
SNNA

Crestwood Advisors Group’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Crestwood Advisors Group’s Portfolio SNNA Stock Details SNNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-14,750
Closed -$219K – 182
2018
Q3 		$219K Hold
14,750
– – 0.02% 155
2018
Q2 		$221K Sell
14,750
-13,750
-48% -$233K 0.02% 156
2018
Q1 		$535K Buy
28,500
+17,500
+159% +$306K 0.04% 100
2017
Q4 		$200K Buy
+11,000
New +$233K 0.02% 177

Other funds holding SNNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crestwood Advisors Group's SNNA Position: Q4 2018 in Review

Crestwood Advisors Group sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q4 2018, closing a stake of 14,750 shares — an estimated $219K sold.

Crestwood Advisors Group first reported a position in SNNA in Q4 2017 and held it in 4 quarters. The position peaked at $535K in Q1 2018. 60 funds tracked by Wall St. Rank hold SNNA as of Q4 2018.

  • Crestwood Advisors Group reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • Crestwood Advisors Group sold 14,750 Sienna Biopharmaceuticals, Inc. shares in Q4 2018, an estimated $219K.
  • Crestwood Advisors Group first reported a position in Sienna Biopharmaceuticals, Inc. in Q4 2017 and held it in 4 quarters.
  • Crestwood Advisors Group's Sienna Biopharmaceuticals, Inc. position peaked at $535K in Q1 2018.
  • 60 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q4 2018.

Based on Crestwood Advisors Group's 13F filing for Q4 2018, filed 14 Feb 2019.